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Introduction
The first hydraulic artificial urinary sphincter (AUS) was 
introduced by Scott in 1974.1 Over the following decade, the 
device has undergone several minor modifications until 
1987, when the current AMS-800™ (AMS; American 
Medical Systems, Minnetonka, MN, USA) was released.2 
Until today, the AMS has become the most widely used AUS 
and ‘gold standard’ for the treatment of moderate to severe 
stress urinary incontinence (SUI).3 Nonetheless, since its 
first description more than 40 years ago, the device remained 
mostly unchanged and still consists of three components: a 
pressure-regulating balloon (PRB), a scrotal pump and a cuff 
placed around the bulbar urethra.1
The demand on reliable AUS models is growing because of 
the increasing number of prostatectomies worldwide, with SUI 
rates of up to 30%4 consecutively deteriorating continence-
related quality of life.5 However, despite excellent outcome 
regarding continence,6 long-term revision rates of up to 85% 
due to mechanical failure, and explantation rates of up to 20% 
due to urethral cuff erosion and/or infection, remain high.7
In 2006, the novel hydraulic FlowSecure™ AUS (FS) was 
developed (and revised in 2012) to improve the rate of seque-
lae due to three changes: the single component construction, 
the additional stress relief balloon (SRB) and a self-sealing 
port at the scrotal pump8 (Figure 1). First of all, avoiding 
multiple tubing components is considered to reduce the rates 
of postoperative device infections and long-term rates of 
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mechanical failures. Second, since pressure-induced urethral 
tissue hypoxia is suspected to be the main pathophysiologic 
mechanism leading to urethral atrophy,9 the SRB, which pro-
vides lower cuff pressures during rest and conditional ele-
vated pressures during periods of stress, is expected to 
counteract this process.10 Finally, regarding the self-sealing 
port, the device can be pressurized in the range from 0 to 
80 cm H2O,8 depending on the continence status, by injecting 
or withdrawing saline at any time postoperatively. To our 
knowledge, no data have been published proving this stress-
relieving mechanism by urethral pressure profile (UPP) in 
vivo. The aim of this case series was to assess this principle 
by UPP and to compare the intraurethral pressures in the cuff 
area of the FS and AMS. The new FS was designed to create 
less urethral pressure than the well-tried AMS. This differ-
ence has – to our knowledge – never been evaluated via UPP. 
In addition, patient satisfaction and continence situation was 
evaluated.
Case series
Clinical characteristics
Eight male patients with previous AUS implantation (FS 
n = 4 and AMS n = 4) were prospectively assessed with uro-
dynamic investigation (UDI) and UPP in this case series 
after giving their written informed consent. AUS implanta-
tion was performed in all patients by the same surgeon, and 
cuffs were placed periurethrally. Cause of SUI was radical 
prostatectomy in six patients, transurethral prostate resection 
in one patient and high-intensity focussed ultrasonography 
(HIFU) in one patient. All patients had pelvic floor muscle 
training and conservative incontinence treatment for at least 
12 months before AUS implantation, and three patients (3/4) 
in the FS group had previous unsuccessful male sling sur-
gery. Incontinence was quantified by the number of used 
pads per day and continence-related quality of life was asked.
UDIs
UDI was performed in the FS and the AMS group after a 
median postoperative period of 24 (17–31) weeks and 79 
(49–288) weeks, respectively. The examination was per-
formed in supine position with a MMS solar silver system 
(Medical Measurement Systems B.V, AN Eschede, The 
Netherlands) using T-DOC air-charged urodynamic cathe-
ters (Laborie Medical Technologies, Mississauga, ON, 
Canada). For analysis, MMS Database software version 
9.1aa, Build 2595 (Medical Measurement Systems B.V) was 
used. UPP was performed with a pulling speed of 2 mm/s of 
the measurement catheter at maximum bladder capacity. All 
UPPs showed two peaks: the first in the membranous urethra 
and the second in the cuff area of the bulbar urethra. Three 
measurements were performed in every patient during rest-
ing and coughing in supine position.
Statistical analyses
Due to the small number of subjects in each arm (FS n = 4 
and AMS n = 4), the validity of statistical analyses is limited. 
Therefore, we resigned to use any statistical test and limited 
ourselves instead to a descriptive presentation of the data 
with medians and their corresponding ranges.
Results
Patient characteristics are shown in Tables 1 and 2. Median 
age was 73 (68–78) years in the FS and 72 (69–76) years in 
the AMS group. Before AUS implantation, the median pad 
use in the FS and AMS group was 4 (3–4) and 4.5 (2–6) 
pads/day, respectively. All patients reported on an unsatis-
factory continence-related quality of life before surgery. The 
median postoperative period between AUS implantation and 
UDI was 24 (17–31) weeks in the FS and 79 (49–288) weeks 
in the AMS group. After surgery, pad usage had declined in 
both groups to 1.5 (0–4) pads/24 h in the FS and 1 (1–2) 
pads/24 h in the AMS group. At the time of UDI, seven of 
eight patients reported on a satisfactory quality of life, and 
one patient in the FS group remained unhappy.
UPP showed a double-peaked curve (Figures 2 and 3) in 
both AUS systems, with the first peak in the membranous 
urethra and the second higher peak in the AUS cuff area of 
the bulbar urethra. At rest, the median pressure in the cuff 
region was 74 (38–117) cm H2O in the FS and 102 (95–
110) cm H2O in the AMS group (Table 3). During coughing, 
Figure 1. The design of the FlowSecure™ AUS.
1: cuff; 2: pump unit; 3: stress relief balloon; 4: pressure regulating balloon.
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median pressure in the cuff region in the FS rose to 135 (54–
162) cm H2O and 202 (128–216) cm H2O in the AMS group. 
No leakage occurred during coughing in both groups. In 
addition, median residual volume assessed by free uroflow-
metry was 15 (0–45) mL in the FS and 0 (0–25) mL in the 
AMS group. No serious adverse events have been observed 
after UDI. One patient had to be treated with antibiotics due 
to a symptomatic urinary tract infection (UTI) after UDI.
Discussion
In this case series, patients in the FS group had lower 
median urethral pressures in the cuff region measured by 
UPP as compared to patients with the AMS. Furthermore, 
pressure transmission from the abdomen to the cuff, by 
the extraperitoneally placed SRB, could be observed 
through pressure amplitudes (Table 3). Interestingly, this 
was also detected in the AMS group. We interpret this 
phenomenon due to two main causes: additive transmis-
sion of the pelvic floor pressure to the cuff and the guard-
ing reflex. However, if this behaviour could be proven in 
a larger AMS patient collective, the necessity of the addi-
tional SRB regarding continence improvement during 
stress might be questioned.
In addition, it must be emphasized that exact pressure-
amplitude quantification is limited due to the fact that pure 
cuff pressure could not be measured directly in situ. Instead, 
urethral pressure was assessed, which is not only caused by 
the cuff but also by cofactors such as the urethra, corpus 
spongiosum and the pelvic floor. Therefore, only estimations 
on cuff pressures and amplitudes can be made with the exist-
ing data. Nonetheless, our observations indicate that higher 
urethral pressures in the AMS group might reflect higher 
system pressure compared to the FS group.
Finally, regarding clinical outcomes, patients in both 
groups showed similar improvements of the pad usage and 
continence-related quality of life.
In 2006, the innovators group8 published preliminary data 
of the largest FS patient cohort so far. Nine male patients, 
having a FS implanted for SUI after prostatectomy and tran-
surethral prostate resection, were included in this observa-
tional study, with a follow-up of 12 months. Two devices 
needed to be explanted within the first 3 months postopera-
tively: the first, being removed after 8 weeks due to a second-
ary undone cuff fixation, therefore, not applying any pressure 
to the urethra, and the second, being removed after 3 months 
because of a fracture at the joint between the tubing and the 
cuff. Both problems were interpreted as mechanical issues 
Table 1.  Patients’ characteristics (FlowSecure™).
1 2 3 4 Median
Age 78 74 68 71 73
Reason for incontinence Radical 
prostatectomy
TUR-P Radical prostatectomy Radical 
prostatectomy
 
T-Stadium (only prostate 
cancer patients)
T2 T2 T3  
Prior therapy Physiotherapy, 
male sling
Physiotherapy, 
male sling
Physiotherapy, male sling Physiotherapy  
Pad use before AUS (per day) 4 3–4 3–4 4 4
Bladder capacity 400 mL 202 mL 660 mL 200 mL  
Flow max 11 mL/s 6 mL/s 25 mL/s 20 mL/s  
Residual urine 30 mL No No No  
Urine dip test NAD NAD Leukocytes: 20–25/visual 
field, nitrite positive
NAD  
Urine culture No growth Mixed flora Klebsiella pneumoniae, 
E. coli
Mixed flora  
Surgery time 81 min 140 min (incl. 
hernia surgery)
120 min 165 min (incl. 
hernia surgery)
 
Cuff size 3.5–4 cm 3.5–4 cm 4.5 cm  
Time to activation 7 weeks 8 weeks 8 weeks 6 weeks  
Time to urodynamic 
evaluation
31 weeks 19 weeks 17 weeks 29 weeks 24 weeks
Pad use postoperative 4 1–2 0 1 1.5
Bladder capacity 
postoperative
377 mL 259 mL 357 mL  
Flow max postoperative 12.4 mL/s 12.4 mL/s 19.6 mL/s  
Residual urine postoperative 46 mL 4 mL 24 mL No  
NAD: no abnormality detected; TUR-P: transurethral prostate resection; AUS: artificial urinary sphincter.
In selected values, the median has been indicated.
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and lead to subsequent changes in the manufacturing pro-
cess. UPPs were carried out in the remaining seven patients 
3 months postoperatively. The mean urethral pressure (±SD) 
in the cuff area, calculated from the difference between the 
peak and the baseline pressure at rest, was 39.4 
(±14.7) cm H2O. In comparison, urethral pressures observed 
at rest in our four FS patients were clearly higher. However, 
this might be coincidence due to the small patient number 
and/or methodological reasons, since we have not measured 
and subtracted the baseline urethral pressure.
Regarding the relationship between cuff pressure and ure-
thral atrophy, a recent publication by Bugeja et al.11 caused 
this hypothesis to totter. First, evidence supporting a rela-
tionship between high cuff pressure, urethral hypoxia and 
atrophy has never been published so far. Second, the devel-
opment of a mesothelial sheath encapsuling the cuff and 
causing extrinsic urethral constriction might be an alterna-
tive explanation.
Regarding clinical improvement, mean pad usage 
declined from 3.3 to 1.6 pads/24 h at 12 months, which was 
Table 2. Patients’ characteristics (AMS-800™).
1 2 3 4 Median
Age 71 76 69 73 72
Reason for incontinence Radical 
prostatectomy
Radical 
prostatectomy
Radical 
prostatectomy
HIFU  
T-Stadium T4 T2 T2 T2  
Prior therapy Physiotherapy Physiotherapy Physiotherapy, 
duloxetine
Physiotherapy  
Pad use before AUS (per day) 2–3 3–5 3–4 5–6 3.75
Bladder capacity 427 mL  
Flow max 12 mL/s  
Residual urine 22 mL  
Urine dip test NAD NAD Leukocytes: 70/µL, 
nitrite negative
 
Urine culture No growth No growth Mixed flora  
Surgery time 85 min 72 min 123 min  
Cuff size 4 cm 4 cm 4.5 cm  
Time to activation 6 weeks 6 weeks 8 weeks  
Time to urodynamic evaluation 75 weeks 83 weeks 49 weeks 288 weeks 79 weeks
Pad use postoperative 1 1 2 1 1
Bladder capacity postoperative 534 mL 587 mL 399 mL 600 mL  
Flow max postoperative 21.8 mL/s 21.3 mL/s 38.7 mL/s 3.8 mL/s  
Residual urine postoperative 24 mL No No No  
NAD: no abnormality detected; HIFU: high-intensity focussed ultrasonography; AUS: artificial urinary sphincter.
In selected values, the median has been indicated.
Figure 2. Double-peaked urethral pressure profilometry of the FlowSecure™.
Pura = urethral pressure.
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comparable to the improvement we observed in our patient 
series. Nonetheless, the authors did not perform UPP during 
periods of stress, hence not observing the pressure relief 
mechanism.
To sum up, although our case series is small, findings 
regarding clinical outcome were in general consistent with 
the data published by the group from London.
What are the clinical implications of our case series? The 
FS was developed to provide an alternative AUS for the effi-
cient control of SUI and to improve the shortcomings of the 
market-leading AMS, consecutively lowering revision and 
explantation rates.8 Using a lower urethral pressure in the FS 
is assumed to lower the risk of urethral erosion. Our small 
series did show a lower urethral pressure in the FS compared 
to the AMS. Further studies with a long-term follow-up are 
needed to assess whether the lower urethral pressure will 
also lower the risk of urethral erosion and the need of surgi-
cal revision of the AUS.
In our results, a pressure transformation from the abdo-
men to the urethra can be demonstrated in both FS and AMS 
patients. This finding questions the need of the additional 
SRB in the FS.
From a surgical perspective, particularly the one-piece 
assembly of the FS makes the handling and the implantation 
quick and simple.12 Consecutively, shorter operating time and 
minimized perioperative handling might reduce prosthesis 
infections, leading frequently to explantation of the AUS in 
the first months after surgery.
Up to date, no data have been published regarding 
long-term clinical outcomes and revision rates of the FS. 
Our case series has two main limitations: low number of 
patients, which does not allow any statistical analyses, 
and a heterogenic study population with different causes 
of SUI.
First, regarding the low number of patients, the aim of 
this case series was to observe the mechanism of the pres-
sure course and its transmission from the abdomen to the 
cuff. In our view, this principle can be answered with a low 
number of patients. Since almost all patients had a long 
way of suffering from SUI and insufficient treatment 
behind them, we decided not to expose more patients to a 
potentially harmful examination, such as the UDI, as the 
principle questions of the study could be answered. Despite 
stringent hygienic measurements and very careful catheter 
placement, one patient suffered from a UTI after the urody-
namic examination.
Conclusion
It remains unclear if the trade-off in favour of lower cuff 
pressures, and consecutively lower intraurethral pressures, 
holds truly long-term benefits regarding device revision, 
Table 3. Comparison of the median urethral pressure in the cuff region.
FlowSecure™ AMS-800™
Median Prest 74 (38–117) cm H2O 102 (95–110) cm H2O
Mean Pmax during coughing 135 (54–162) cm H2O 202 (128–216) cm H2O
∆ P 61 cm H2O 100 cm H2O
P: urethral pressure.
The values in the table are continuous variables with mean value and minimum and maximum range.
Figure 3. Double-peaked urethral pressure profilometry of the AMS-800™.
Pura = urethral pressure.
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explantation and patient satisfaction. For this reason, long-
term data of sufficiently powered and well-designed pro-
spective randomized trials, comparing both devices, are 
highly needed to make final recommendations.
In conclusion, the newer FS needs some adaptions in clin-
ical practice regarding postoperative management to secure 
high quality in care of those highly challenging patients. 
However, trials with longer follow-up are needed to pinpoint 
on possible new challenges, such as scrotal infections due to 
manipulations at the self-sealing port or iatrogenic device 
lesions, and their solutions and prophylaxis.
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